{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nab-Sirolimus", "query": { "intervention": "nab-Sirolimus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nab-Sirolimus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T12:47:41.233Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07104331", "title": "SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelioid Hemangioendothelioma (EHE)" ], "interventions": [ { "name": "nab-Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2026-02-24", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 6, "location_summary": "Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07104331" }, { "nct_id": "NCT00635284", "title": "ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2007-12-01", "completion_date": "2011-06-01", "has_results": false, "last_update_posted_date": "2019-10-18", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00635284" }, { "nct_id": "NCT03657420", "title": "Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-05-30", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657420" }, { "nct_id": "NCT02587325", "title": "Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-04-01", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 6, "location_summary": "Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Torrance", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587325" }, { "nct_id": "NCT01376310", "title": "GSK1120212 Rollover Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "Docetaxel + GSK1120212", "type": "DRUG" }, { "name": "Erlotinib + GSK1120212", "type": "DRUG" }, { "name": "Pemetrexed + GSK1120212", "type": "DRUG" }, { "name": "Carboplatin + GSK1120212", "type": "DRUG" }, { "name": "Nab-paclitaxel + GSK1120212", "type": "DRUG" }, { "name": "Gemcitabine + GSK1120212", "type": "DRUG" }, { "name": "Everolimus + GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2010-11-02", "completion_date": "2018-01-18", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376310" }, { "nct_id": "NCT02009332", "title": "Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-04-09", "completion_date": "2019-12-01", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009332" }, { "nct_id": "NCT02975882", "title": "Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus Albumin-bound Nanoparticles", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 33, "start_date": "2017-08-15", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02975882" }, { "nct_id": "NCT05103358", "title": "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor", "Tumor, Solid", "Metastasis", "Metastatic Cancer", "Cancer", "Cancer Metastatic", "Tumors", "Neoplasms", "Neoplasm Metastasis", "Solid Tumor", "Advanced Solid Tumor", "Advanced Cancer", "Malignant Solid Tumor", "Malignant Solid Neoplasm", "Malignant Neoplasm", "Malignant Tumor", "TSC", "TSC1", "TSC2", "Metastatic Solid Tumor", "Metastatic Neoplasm" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 120, "start_date": "2022-02-15", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 159, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103358" }, { "nct_id": "NCT05661461", "title": "Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid", "Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-11-23", "completion_date": "2026-08-01", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 2, "location_summary": "San Antonio, Texas • West Valley City, Utah", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05661461" }, { "nct_id": "NCT03670030", "title": "A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert Ramirez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-11-05", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-09-05T12:47:41.233Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670030" } ] }